ArticleExpert opinion on drug discovery2011
Can Functional Magnetic Resonance Imaging Improve Success Rates in CNS Drug Discovery?
Article in Expert opinion on drug discovery, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Oxytocin alters patterns of brain activity and amygdalar connectivity by age during dynamic facial emotion identification.Neurobiology of aging · 2019Trial
- Spatial heterogeneity of the relation between resting-state connectivity and blood flow: an important consideration for pharmacological studies.Human brain mapping · 2014Trial
- Article
- Validity of mental and physical stress models.Neuroscience and biobehavioral reviews · 2024Review
- STING controls opioid-induced itch and chronic itch via spinal tank-binding kinase 1-dependent type I interferon response in mice.Journal of neuroinflammation · 2023Article
- Oxycodone-Mediated Activation of the Mu Opioid Receptor Reduces Whole Brain Functional Connectivity in Mice.ACS pharmacology & translational science · 2019Article
- Mechanisms Underlying Bone and Joint Pain.Current osteoporosis reports · 2018Review
- Migrainomics - identifying brain and genetic markers of migraine.Nature reviews. Neurology · 2017Review
- Commentary on Schmitz et al. (2017): Advancing medication development for addiction-behavioral and neuroimaging outcomes as indirect biomarkers of target engagement.Addiction (Abingdon, England) · 2017Article
- Medications development for the treatment of alcohol use disorder: insights into the predictive value of animal and human laboratory models.Addiction biology · 2017Review
- Biomarkers, designs, and interpretations of resting-state fMRI in translational pharmacological research: A review of state-of-the-Art, challenges, and opportunities for studying brain chemistry.Human brain mapping · 2017Review
- Random Forest Segregation of Drug Responses May Define Regions of Biological Significance.Frontiers in computational neuroscience · 2016Article
- Taking the headache out of migraine.Neurology. Clinical practice · 2015Article
- N-acetyl-L-leucine accelerates vestibular compensation after unilateral labyrinthectomy by action in the cerebellum and thalamus.PloS one · 2015Article
- Lost but making progress--Where will new analgesic drugs come from?Science translational medicine · 2014Review
- Future directions for research in autism spectrum disorders.Journal of clinical child and adolescent psychology : the official journal for the Society of Clinical Child and Adolescent Psychology, American Psychological Association, Division 53 · 2014Article
- Surgically induced neuropathic pain: understanding the perioperative process.Annals of surgery · 2013Review
- Personalized medicine and opioid analgesic prescribing for chronic pain: opportunities and challenges.The journal of pain · 2013Review
- Pharmacologic magnetic resonance imaging (phMRI): imaging drug action in the brain.NeuroImage · 2012Review
- Migraine changes the brain: neuroimaging makes its mark.Current opinion in neurology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
introductionThe bar for developing new treatments for CNS disease is getting progressively higher and fewer novel mechanisms are being discovered, validated and developed. The high costs of drug discovery necessitate early decisions to ensure the best molecules and hypotheses are tested in expensive late stage clinical trials. The discovery of brain imaging biomarkers that can bridge preclinical to clinical CNS drug discovery and provide a 'language of translation' affords the opportunity to improve the objectivity of decision-making. AREAS COVERED: This review discusses the benefits, challenges and potential issues of using a science based biomarker strategy to change the paradigm of CNS drug development and increase success rates in the discovery of new medicines. The authors have summarized PubMed and Google Scholar based publication searches to identify recent advances in functional, structural and chemical brain imaging and have discussed how these techniques may be useful in defining CNS disease state and drug effects during drug development. EXPERT OPINION: The use of novel brain imaging biomarkers holds the bold promise of making neuroscience drug discovery smarter by increasing the objectivity of decision making thereby improving the probability of success of identifying useful drugs to treat CNS diseases. Functional imaging holds the promise to: (1) define pharmacodynamic markers as an index of target engagement (2) improve translational medicine paradigms to predict efficacy; (3) evaluate CNS efficacy and safety based on brain activation; (4) determine brain activity drug dose-response relationships and (5) provide an objective evaluation of symptom response and disease modification.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.